Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma

BACKGROUND: There is a lack of effective treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Furthermore, the response rate of NPC patients to programmed death 1 (PD-1) inhibitors is approximately 20% to 30%. Thus, we aimed to explore reliable and minimally invasive prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ao, Zhong, Guanqing, Wang, Luocan, Cai, Rongzeng, Han, Runkun, Xu, Caixia, Chen, Shulin, Sun, Peng, Chen, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480072/
https://www.ncbi.nlm.nih.gov/pubmed/34583688
http://dx.doi.org/10.1186/s12935-021-02217-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480072/
https://www.ncbi.nlm.nih.gov/pubmed/34583688
http://dx.doi.org/10.1186/s12935-021-02217-y

Ejemplares similares